Skip to main content
. Author manuscript; available in PMC: 2018 Apr 18.
Published in final edited form as: Clin Cancer Drugs. 2017;4(2):122–128. doi: 10.2174/2212697x04666170817123425

Table 4.

Toxicities in the EM and PM subsets (*: 1 patient had report on toxicity not available, **: 2 patients were excluded because dose adaptation was not confirmed)

EM (200 patients*) PM (18 patients**) p-value
n % n %
No toxicity 62 31 7 39 p =0.7875 (Pearson’s chi-square test)
G1-G2 toxicities 112 56 9 50
Severe toxicities 26 13 2 11